24,194 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Entropy Technologies LP

Entropy Technologies LP acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 24,194 shares of the medical research company’s stock, valued at approximately $6,306,000. Amgen accounts for 0.6% of Entropy Technologies LP’s portfolio, making the stock its 19th biggest position.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen in the third quarter valued at approximately $29,000. Heck Capital Advisors LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $36,000. Livelsberger Financial Advisory bought a new position in shares of Amgen in the third quarter valued at approximately $56,000. Finally, Kennebec Savings Bank bought a new position in shares of Amgen in the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 1.4 %

Amgen stock opened at $293.54 on Friday. The company has a market capitalization of $157.79 billion, a P/E ratio of 38.88, a P/E/G ratio of 3.01 and a beta of 0.56. The firm’s fifty day simple moving average is $272.26 and its 200-day simple moving average is $303.21. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Sell-side analysts forecast that Amgen Inc. will post 20.59 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.24%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 119.21%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.69% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AMGN. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Bank of America raised their target price on shares of Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a report on Thursday. TD Cowen raised their target price on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research note on Friday, January 24th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $313.23.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.